drugset
drugset / Trial / NCT05753033

The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers

NCT05753033 ↗

Phase 1 Completed 56 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase I PK bridging study to evaluate the PK, safety and tolerability of SR750 in healthy subjects.

Timeline

Start
2023-02-28
Primary completion
2023-09-06
Completion
2023-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SR750 Unknown — Oral

Indications

No indication recorded.